Nicholas Brown – 2016 Parliamentary Question to the Department of Health
The below Parliamentary question was asked by Nicholas Brown on 2016-05-26.
To ask the Secretary of State for Health, what information his Department holds on the use of peptide receptor radionuclide therapy treatments to target carcinoid tumours.
George Freeman
Information on the peptide receptor radionuclide therapy treatments funded through the Cancer Drugs Fund (CDF) is shown in the table. It is not known for what type of cancer these treatments have been provided.
|
Number of patients treated in 2011/121 |
Number of patients treated in 2012/131 |
Number of CDF notifications 2013/142 |
Number of CDF notifications 2014/152 |
Number of CDF notifications 2015/16 (to Sept) 2 |
|
|
Peptide receptor radionuclide therapy (to include Lutetium-177 or Yttrium-90 octreotide analogues) |
49 |
117 |
152 |
229 |
116 |
1 Source: Strategic Health Authority returns to the Department of Health
2 Source: NHS England
Information on the number of peptide receptor radionuclide therapy treatments provided outside of the CDF is not collected.
